Virpax Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™Business Wire • 12/08/21
Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent DevelopmentsBusiness Wire • 11/15/21
Virpax to Present at the NobleCon Online Pain Management Investor Forum on Channelchek.com on October 7, 2021Business Wire • 10/01/21
Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and ChildrenBusiness Wire • 09/20/21
Virpax® Pharmaceuticals Announces Closing of $40 Million Public Offering of Common StockBusiness Wire • 09/16/21
Virpax® Pharmaceuticals Announces Pricing of $40 Million Public Offering of Common StockBusiness Wire • 09/14/21
Virpax Pharmaceuticals Announces Poster Presentation for Envelta™ at PAINWeek 2021Business Wire • 09/02/21
VRPX Stock: What Investors Are Saying About Virpax Pharma as Shares Continue to FlyInvestorPlace • 08/18/21
Virpax's stock rockets nearly 5-fold in 2 days after upbeat FDA response to its SARS-CoV-2 inhibitorMarket Watch • 08/18/21
Virpax soars 292% after receiving initial FDA guidance on its treatment for SARS and fluBusiness Insider • 08/17/21
VRPX Stock: 6 Things for Virpax Pharma Investors to Know as Shares Rocket Over 250%InvestorPlace • 08/17/21
Virpax Pharmaceuticals Reports 2021 Second Quarter Results and Recent DevelopmentsBusiness Wire • 08/10/21
Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F.Business Wire • 07/30/21